Chagas' disease affects over 18 million people in Latin America. The agent responsible is a protozoan parasite, Trypanosoma cruzi, transmitted by haematophagous insects. For survival in the host's organism, it uses several strategies, but especially one of inhibiting the host's immune response. Research scientists from the IRD and INSERM (1) who are studying this trypanosome found that one of the proteins it secretes, Tc52, is a virulence factor that plays a pivotal role in the infection mechanism. Combining different in–vitro and in-vivo approaches, they brought into evidence its role in the development of infection and performed the molecular characterization by peptide analysis of the minimal sequence of Tc52 that carries immunosuppressive activity. Knowledge of the biological activity of this factor raises the prospects for developing vaccination strategies or drugs to combat T. cruzi.
Chagas' disease – or American trypanosomiasis – is a parasitic illness which affects nearly 20 million people mainly in tropical regions of Central and South America. The aetiological agent that causes it is a flagellate protozoan, Trypanosoma cruzi, transmitted to humans by haematophagous insects (Reduviidae). Research scientists from the IRD research unit "Pathogénie des Trypanosomatidae" and co-workers from INSERM have studied the parasite's development cycle, its virulence and its involvement in the infection process, with a view to identifying possible prevention and control methods. Using techniques of cellular and molecular biology, and of biochemistry, they sought to identify the nature and function of T. cruzi genes which code for the factors responsible for the virulence, in particular a protein called Tc52.
As in any parasitic disease, the pathogen's ability to survive in its vertebrate host depends on many mechanisms, especially one which weakens the host's immune response. In Chagas' disease, during its life-cycle in humans T. cruzi takes on two forms, an infective flagellate one (trypomastigote) which circulates and reproduces in the blood and another intracellular one without flagellum (amastigote), which in its turn multiplies to produce another batch of circulating forms. These two forms prove to be able to secrete this protein Tc52. The research team revealed it to have several activities, including enzyme activity (2) and an immunosuppressive activity. The protein released by T. cruzi influences in a complex way the physiology of the host cell. It acts on cells of the immune system, the macrophages and the dendritic cells, and notably blocks the production of interleukin 2 (IL-2), a cytokine necessary for T-lymphocyte proliferation, in this way exerting an immunosuppressive activity.
Experimental infections with T. cruzi have been conducted in the laboratory on mice immunized beforehand with this protein. These led to a reduction in mortality rate during the acute phase of the disease, showing that it is possible to protect them partially against such infection. In addition, mutant parasites obtained by targeted deletion of a protein-coding allele of the Tc52 gene have been used for analysis, again in vivo, of the effects of a decrease in Tc52 production on the host immune response and the development of symptoms of the chronic phase, especially the inflammation reaction. Infection by these mutants results in normal production of IL-2 and attenuation of these symptoms. The research team subsequently performed the molecular characterization of the minimal amino-acid sequence, or minimum functional domain, of the protein responsible for the immunosuppressive activity.
The results of this work as a whole demonstrate that this protein secreted by T. cruzi plays a key role in the development of the infection and the pathological manifestations of Chagas' disease. As its enzyme and immunosuppressive activity are now known, the prospect emerges of developing biochemical strategies– involving inhibition of Tc52's enzyme activity by anti-parasitic drugs – or vaccines, against T. cruzi. Research projects are currently planned in conjunction with other institutes (3) with the objective of molecular characterization of particular receptors of this protein situated on the macrophages and the dendritic cells, and of devising specific inhibitors. In this way they will contribute to formulation of the tools necessary for drug development.
(1) UR 008 Pathogénie des Trypanosomatidae of the IRD
(2) thioltransferase, involved in the parasite's protection against oxidation stress.
(3) CNRS Laboratoire d'immunologie et chimie thérapeutique (UPR 9021) at Strasbourg and INSERM joint research unit (UMR) 564 of Angers Faculty of Medicine.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
Don't be too timid and squeamish about your actions. All life is an experiment. The more experiments you make the better.
-- Ralph Waldo Emerson